• Protocol Short Name and Number: SR-aGVHD, 2002
• Protocol Long Name: A Phase 3, Randomized, Open-Label, Multicenter Study, to Compare T-Guard to Ruxolitinib for the Treatment of Patients with Grade III or IV Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)
• Protocol Synopsis (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # 2002 Co-Chair: John Levine, MD
   • BMT CTN # 2002 Co-Chair: Gabby Meyers, MD
   • BMT CTN # 2002 Co-Chair: Gérard Socié, MD
   • BMT CTN # 2002 Protocol Officer: Mehdi Hamadani, MD
   • BMT CTN # 2002 Protocol Coordinator: 2002DCC@emmes.com

• Keywords: Graft vs. Host Disease, GVHD, Graft versus Host Disease, T-Guard, TGuard, Ruxolitinib, Steroid Refractory, Steroid-Refractory, Anti-CD3/CD7 Immunotoxin, Xenikos, GVHD Treatment

• Protocol Short Name and Number: BEAT-MS, 1905
• Protocol Long Name: A Multicenter Randomized Controlled Trial of Best Available Therapy versus Autologous Hematopoietic Stem Cell Transplant for Treatment-Resistant Relapsing
• Key Personnel​​​​

1. • BMT CTN 1905 Co-Chair: Jeffrey A. Cohen, MD
   • BMT CTN 1905 Co-Chair: George E. Georges, MD
   • BMT CTN 1905 Co-Chair: Paolo A. Muraro, MD, PhD
   • BMT CTN 1905 Chair: Marcelo Pasquini, MD; mpasquini@mcw.edu
   • NIAID Protocol Coordinator: Sean McCarthy, RN, MS; sean.mccarthy@nih.gov
   • BMT CTN DCC Coordinator: Amy Foley; afoley@nmdp.org

• Keywords: Multiple Sclerosis, MS, Autologous Transplant, Auto Transplant, Auto

Note: For the ITN077AI / BMT CTN 1905 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via NIAID/Immune Tolerance Network (ITN). BMT CTN Centers will receive both NIAID/ITN and BMT CTN accrual credits. For questions about the study and how to participate or to access study materials, contact the NIAID protocol coordinator, Sean McCarthy, at sean.mccarthy@nih.gov.

• Protocol Short Name and Number: HIV T-cell, 1903
• Protocol Long Name: (AMC-109) - Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel
  • BMT CTN # 1903 Co-Chair: Rich Ambinder, MD
  • BMT CTN # 1903 Co-Chair: Kieron Dunleavy, MD
  • BMT CTN # 1903 Protocol Officer: Steve Devine, MD
  • BMT CTN # 1903 Protocol Coordinator: Christine Borchert; bmtctn1903@emmes.com
• Keywords: HIV, Autologous Stem Cell Rescue, Autologous Stem Cell Transplant, ASCT, Auto, RESIST, Auto Transplant, Autologous Transplant, HST-NEETs, HSCT, HCT, Pediatric, Child, Children, Teen, Adolescent

• Protocol Short Name and Number: T-Guard for SR aGVHD, 1802
• Protocol Long Name: An Open-Label, Single-Arm, Multicenter Study of Combination anti- CD3/CD7 Immunotoxin (T-Guard) for Steroid-Refractory Acute Graft- versus-Host Disease
• Protocol Synopsis (PDF)
• Key Personnel

1. • BMT CTN # 1802 Co-Chair: John Levine, MD
   • BMT CTN # 1802 Co-Chair: Gabrielle Meyers, MD
   • BMT CTN # 1802 Protocol Officer: Mehdi Hamadani, MD

• Keywords: T-Guard, TGuard, Graft versus Host Disease, Graft vs. Host Disease, GVHD, Xenikos, Anti-CD3/CD7 Immunotoxin, GVHD Treatment, Pediatric, Child, Children, Teen, Adolescent

• Protocol Short Name and Number: AAT GVHD Treatment, 1705
• Protocol Long Name: A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 – Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplant
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # Co-Chair: Amin Alousi
   • BMT CTN # Co-Chair: John Magenau
   • Protocol Officer: Mehdi Hamadani, MD
   • Protocol Coordinator: Erika Hoehn; bmtctn1705@emmes.com

• Keywords: Alpha-1 Antitrypsin, AAT, Graft versus Host Disease, GVHD, Graft vs. Host Disease, GVHD Treatment, Quality of Life, QOL, Patient Reported Outcomes, PROs, Pediatric, Child, Children, Teen, Adolescent

• Protocol Short Name and Number: PROGRESS III – PTCY vs. TAC/MTX / Mi-Immune, 1703/1801
• Protocol Long Name:

1. • BMT CTN 1703: A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
   • BMT CTN 1801: Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)

• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel (BMT CTN 1703)

1. • BMT CTN # 1703 Co-Chair: Shernan Holtan, MD
   • BMT CTN # 1703 Co-Chair: Javier Bolanos-Meade, MD
   • BMT CTN # 1703 Protocol Officer: Mehdi Hamadani, MD
   • BMT CTN # 1703 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1703@emmes.com

• Key Personnel (BMT CTN 1801)

1. • BMT CTN # 1801 Co-Chair: Miguel-Angel Perales, MD
   • BMT CTN # 1801 Co-Chair: Leslie Kean, MD, PhD
   • BMT CTN # 1801 Co-Chair: Ami Bhatt, MD, PhD
   • BMT CTN # 1801 Protocol Officer: Wael Saber, MD, MS
   • BMT CTN # 1801 Protocol Coordinator: Kristy Applegate, MBA;  bmtctn1703@emmes.com

• Keywords: PROGRESS, Mi-Immune, Graft versus Host Disease, GVHD Prophylaxis, GVHD, Post-Transplant Cyclophosphamide, PTCY, Microbiome, Allogeneic Transplant, Allo Transplant, Allo, Unrelated donor, Unrelated, Hematopoietic Stem Cell Transplant, HSCT, HCT, Quality of Life, QOL, Patient Reported Outcomes, PROs, Tacrolimus, TAC, Tacro, Methotrexate, MTX, Mycophenolate Mofetil, MMF, Acute Leukemia, Chronic Myelogenous Leukemia, CML, Myelodysplastic Syndrome, MDS, Chronic Myelomonocytic Leukemia, CMML, Chronic Lymphocytic Leukemia, CLL, Lymphoma, Leukemia

• Protocol Short Name and Number: ECOG-ACRIN EA4151 MCL, 1601
• Protocol Long Name: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
• Key Personnel

1. • BMT CTN # 1601 Protocol Chair: Timothy Fenske, MD
   • BMT CTN # 1601 Chair: Matthew Lunning, MD
   • BMT CTN # 1601 Protocol Coordinator: Christiana Samuel, csamuel@ecog-acrin.org     
   • BMT CTN # 1601 Protocol Coordinator: Amy Foley, afoley@nmdp.org

• Keywords: Auto Transplant, Autologous Hematopoietic Cell Transplant, HCT, Autologous Transplant, Auto, Rituximab, Mantle Cell Lymphoma, MCL

Note: For the ECOG-ACRIN EA4151/BMT CTN 1601 study, the BMT CTN is endorsing the study and providing accrual credit. Centers participate via their NCTN group. BMT CTN Centers will receive both NCTN and BMT CTN accrual credits. The protocol may be accessed through the CTSU website: https://www.ctsu.org  For questions about the study and how to participate, contact the ECOG-ACRIN protocol coordinator, Haleigh Wetzel, at hwetzel@ecog-acrin.org or 857-504-2900, or the CTSU Help Desk at  ctsucontact@westat.com or 1 888 823-5923.

• Protocol Short Name and Number: AML FLT3 Maintenance Therapy, 1506
• Protocol Long Name: A multi-center, randomized, double-blind, placebo-controlled Phase III trial of the FLT3 inhibitor gilteritinib administered as maintenance therapy following allogeneic transplant for patients with FLT3/ITD AML
• Protocol (PDF)
• Key Personnel

1. • BMT CTN # 1506 Co-Chair: Mark Levis, MD
   • BMT CTN # 1506 Co-Chair: Yi-Bin Chen, MD
   • BMT CTN # 1506 Protocol Officer: Mehdi Hamadani, MD
   • BMT CTN # 1506 Protocol Coordinator: Laxman Saripilla; 1506DCC@emmes.com

• Keywords: AML, Acute Myelogenous Leukemia, FLT3, Maintenance Therapy, Maintenance, FLT3 inhibitor gilteritinib

• Protocol Short Name and Number: STRIDE2, 1503
• Protocol Long Name: A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults with Severe Sickle Cell Disease
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # 1503 Co-Chair: Lakshmanan Krishnamurti, MD
   • BMT CTN # 1503 Co-Chair: Mark Walters, MD
   • BMT CTN # 1503 Protocol Officer: Mary Eapen, MD, MS
   • BMT CTN # 1503 Protocol Coordinator: bmtctn1503@emmes.com

• Keywords: Sickle Cell Disease, SCD, Sickle Cell, SC, Adolescents, Unrelated Donor, Allogeneic Transplant, Allo Transplant, Quality of Life, QOL, Pediatric, Child, Children, Teen, Adolescent

• Protocol Short Name and Number: SR aGVHD, 1501
• Protocol Long Name: A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients with Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease
• Protocol (PDF)
• Protocol Synopsis (PDF)
• Informed Consent and Assent Local IRBs (PDF)
• Informed Consent and Assent NMDP IRB (PDF)
• Frequently Asked Questions (PDF)
• Key Personnel
  • BMT CTN # 1501 Protocol Co-Chair: Joseph Pidala, MD, PhD
  • BMT CTN # 1501 Protocol Co-Chair: Margaret MacMillan, MD
  • BMT CTN # 1501 Protocol Officer: Mehdi Hamadani, MD      
  • BMT CTN # 1501 Protocol Coordinator: bmtctn@emmes.com
• Keywords: Graft versus Host Disease, GVHD, Graft vs. Host Disease, GVHD Treatment, Sirolimus, Quality of Life, QOL, Ann Arbor, Pediatric, Child, Children, Teen, Adolescent

This study reached its accrual goal on February 16, 2018 and is now closed to new patient enrollment.

• Protocol Short Name and Number:  DFCI 10-106/ BMT CTN 1304 DETERMINATION
• Protocol Long Name: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age.

• Protocol
• Key Personnel
  • BMT CTN # 1304  Protocol Chair: Paul Richardson
  • BMT CTN # 1304  Protocol Coordinator: Amy Foley afoley@nmdp.org          
• Keywords: Lenalidomide, Bortezomib, Dexamethasone, RVD, Multiple Myeloma, MM, Quality of Life, QOL, Auto Transplant, Autologous Transplant, Auto, Consolidation, Maintenance, Pediatric, Child, Children, Teen, Adolescent

• Protocol Short Name and Number: CNI-free GVHD (PROGRES II), 1301
• Protocol Long Name: A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # 1301 Co-Chair: Miguel-Angel Perales, MD
   • BMT CTN # 1301 Co-Chair: Leo Luznik, MD
   • BMT CTN # 1301 Protocol Officer: Marcelo Pasquini, MD, MS
   • BMT CTN # 1301 Protocol Coordinator: Kristy Applegate, MBA; bmtctn1301@emmes.com

• Keywords: Allo Transplant, Allogeneic Transplant, Allo, Unrelated, Unrelated Donor, HSCT, HCT, Graft versus Host Disease, GVHD, Graft vs. Host Disease, Prophylaxis, Quality of Life, QOL, Calcineurin Inhibitor-Free, CNI, Tacrolimus, TAC, Methotrexate, MTX, Acute Leukemia, Myelodysplastic Syndrome, MDS, Chronic Myelomonocytic Leukemia, CMML, Leukemia, PROGRESS, CliniMACS, Pediatric, Child, Children, Teen, Adolescent

• Protocol Short Name and Number: RICHI, 1204
• Protocol Long Name: Reduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies.
• Protocol (PDF)
• Protocol Synopsis (PDF)
• Informed Consent and Assent
• Frequently Asked Questions
• Key Personnel
  • BMT CTN # 1204 Protocol Co-Chair: Carl Allen, MD
  • BMT CTN # 1204  Protocol Co-Chair: M. Pulsipher, MD
  • BMT CTN # 1204 Protocol Officer: Mary Eapen, MD
  • BMT CTN # 1204 Medical Monitor: Liza Thiel, MD
• Keywords: RICHI, Hemophagocytic, Primary Immune Deficiencies, Epstein-Barr Virus, EBV, Epstein Barr, CAEBV, Chronic Granulomatous Disease, CGD, X-linked Hyper IgM Syndrome, HIGM1, IPEX, Leukocyte Adhesion Syndrome, LAD-I, LAD, Hemophagocytic Lymphohistiocytosis, HLH, Reduced Intensity Conditioning, Allogeneic Transplant, Allo Transplant, Allo, Unrelated, Unrelated Donor, Pediatric, Child, Children, Teen, Adolescent

Accrual for the BMT CTN 1204 trial closed on December 4, 2015.

• Protocol Short Name and Number: Biomarkers, 1202
• Protocol Long Name: Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT.
• Protocol (PDF), version 3.0 dated March 17, 2015
• Protocol Synopsis (PDF), version 3.0 dated March 17, 2015
• Summary of Changes from version 2.0 to 3.0 (PDF)
• Informed Consent and Assent (PDF), version 3.0 dated March 17, 2015
• FAQs (PDF)
• Key Personnel

             BMT CTN# 1202 Co-Chair: John Levine, MD 

             BMT CTN# 1202 Protocol Co-Chair: John Hansen, MD 

             BMT CTN# 1202 Protocol Officer and Medical Monitor: Wael Saber, MD

             BMT CTN# 1202 Protocol Coordinator: bmtctn1202@emmes.com           

• Keywords: Biomarkers, Correlative Studies, Biological Samples, Biospecimen, Pediatric, Child, Children, Teen, Adolescent

The BMT CTN is committed to including widespread transplant community participation in these trials. For information on how to apply to participate on this study, please contact the Protocol Coordinator at bmtctn1202@emmes.com for details.

• Protocol Short Name and Number: RIC vs Hypometh for MDS, 1102
• Protocol Long Name: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome
• Protocol (PDF)
• ICFs (PDF)
• FAQs (PDF)
• Key Personnel

1. • BMT CTN # 1102 Co-Chair: Corey Cutler, MD, MPH, FRCP(C)
   • BMT CTN # 1102 Co-Chair: Ryotaro (Ryo) Nakamura, MD
   • BMT CTN # 1102 Protocol Officer: Wael Saber, MD, MS
   • BMT CTN # 1102 Protocol Coordinator: Kristy Applegate; bmtctn1102@emmes.com

• Keywords: Myelodysplastic Syndrome, MDS, Allogeneic Transplant, Allo Transplant, Allo, Reduced Intensity Conditioning, RIC, Biologic Assignment, Quality of Life, QOL, Unrelated, Unrelated Donor

• Protocol Short Name and Number: Allo Transplant in HIV, 0903
• Protocol Long Name: Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodyplastic Syndromes in HIV-infected Patients
• Protocol (PDF)
• Informed Consent and Assent
• Frequently Asked Questions
• Key Personnel
  • BMT CTN # 0903 Protocol Chair: Joseph Alvarnas, MD
  • BMT CTN # 0903 Protocol Co-Chair: Richard Ambinder, MD  
  • BMT CTN # 0903 Protocol Officer: Willis Navarro
  • BMT CTN # 0903 Medical Monitor: Tammy Kindwall-Keller, MD
  • BMT CTN # 0903 Protocol Coordinator:  bmtctn@emmes.com
• Keywords: HIV, Allogeneic Transplant, Allo Transplant, Allo, Leukemia, Acute Myelogenous Leukemia, AML, Acute Lymphocytic Leukemia, ALL, Myelodysplastic Syndrome, MDS, Lymphoma, HL, NHL, Unrelated, Unrelated Donor, Pediatric, Child, Children, Teen, Adolescent

The BMT CTN 0903 study closed to new patient accrual on December 3, 2015.

• Protocol Short Name and Number: Full vs RIC in MDS/AML, 0901
• Protocol Long Name: A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia
• Protocol (PDF)
• Protocol Synopsis (PDF)
• Informed Consent (PDF)
• Key Personnel
  • BMT CTN # 0901 Protocol Co-Chair: Mitchell Horwitz, MD
  • BMT CTN # 0901 Protocol Co-Chair: Bart Scott, MD  
  • BMT CTN # 0901 Protocol Officer: Marcello Pasquini, MD
  • BMT CTN # 0901 Medical Monitor: Bipin Savani, MD
  • BMT CTN # 0901 Protocol Coordinator:  bmtctn@emmes.com
• Keywords: Allogeneic Transplant, Allo Transplant, Allo, Reduced Intensity Conditioning, RIC, Myeloablative Conditioning, Acute Myelogenous Leukemia, AML, Myelodysplastic Syndrome, MDS, Unrelated, Unrelated Donor. Quality of Life, QOL

This study was closed to new patient accrual on April 18, 2014.

• Protocol Short Name and Number:  CALGB 100701/ BMT CTN 0804 CLL
• Protocol Long Name: Phase II Study of Reduced- Intensity Allogeneic Stem Cell Transplant For High Risk Chronic Lymphocytic Leukemia (CLL)
• For access to Protocol documents please visit the CTSU site: https://www.ctsu.org
• Key Personnel
  •  BMT CTN # 0804 Protocol Chair: Richard T. Maziarz, MD
  •  BMT CTN # 0804 Protocol Officer: Mary Horowitz, MD
  •  Alliance Regulatory Group: regulatory@alliancenctn.org
• Keywords: CALGB, 100701, Reduced Intensity, RIC, Chronic Lymphocytic Leukemia, CLL, Leukemia, Allogeneic Transplant, Allo Transplant, Allo, Unrelated, Unrelated Donor

This study has reached its final accrual goal; the study closed to new patient accrual on January 27, 2014.

• Protocol Short Name and Number: aGVHD Phase III, 0802
• Protocol Long Name: A Multi-Center, Randomized, Double Blind, Phase III Trial Evaluating Corticosteroids with Mycophenolate Mofetil vs. Corticosteroids with Placebo as Initial Systemic Treatment of Acute GVHD
• Protocol (PDF)
• Informed Consent and Assent 
• Frequently Asked Questions 
• Key Personnel
  • BMT CTN # 0802 Protocol Chair: Javier Bolanos-Meade, MD  
  • BMT CTN # 0802 Protocol Co-Chair: Vincent T. Ho, MD  
  • BMT CTN # 0802 Protocol Officer: Mary Horowitz, MD  
  • BMT CTN # 0802 Protocol Coordinator: bmtctn@emmes.com
  • BMT CTN # 0802 Medical Monitor: Dianna Howard, MD
• Keywords: Graft versus Host Disease, GVHD, Graft vs. Host Disease, Treatment, Mycophenolate Mofetil, MMF, Patient Reported Outcomes, PROs, Quality of Life, QOL, Pediatric, Child, Children, Teen, Adolescent

The BMT CTN 0802 study closed to new patient accrual on November 14, 2011.

• Protocol Short Name and Number: 0702 LTFU, 07LT
• Protocol Long Name: Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702
• Protocol (PDF)
• Protocol Synopsis (PDF) 
• Informed Consent 
• Frequently Asked Questions 
• Key Personnel
  • BMT CTN # 07LT Protocol Co-Chair: Amrita Krishnan, MD  
  • BMT CTN # 07LT Protocol Co-Chair: George Somlo, MD  
  • BMT CTN # 07LT Protocol Co-Chair: Ed Stadtmauer, MD
  • BMT CTN # 07LT Protocol Officer: Marcelo Pasquini, MD  
  • BMT CTN # 07LT Medical Monitor: Shannon Smiley, MD
  • BMT CTN # 07LT Protocol Coordinator:  bmtctn@emmes.com
• Keywords: Lenalidomide, Multiple Myeloma, MM, Quality of Life, QOL, Revlimid, Maintenance

This study is a sub-study of BMT CTN 0702. All site with at least one patient enrolled on BMT CTN 0702 are eligible to open this study.

• Protocol Short Name and Number:  SWOG #S0410 /BMT CTN0703 Hodgkin’s Lymphoma
• Protocol Long Name: Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin’s Disease (A BMT Study), Phase II
• For access to Protocol documents please visit the CTSU site: https://www.ctsu.org
• Key Personnel
  • SWOG Protocol Chair: Patrick Stiff, MD
  • BMT CTN # 0703 Protocol Chair: Ginna Laport, MD
  •   SWOG Protocol Officer: Eileen Smith, MD
  • BMT CTN # 0703 Protocol Officer:  MarcieRiches, MD
• Keywords: SWOG, S0410, Hodgkin’s Lymphoma, HL, Auto, Autologous Transplant, Auto Transplant, HCT, HSCT, Tandem, Teen, Adolescent, Child, Children

This study reached target accrual and closed to patient accrual on July 19, 2009.

• Protocol Short Name and Number: Follicular NHL, 0701
• Protocol Long Name: Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin’s Lymphoma Beyond First Complete Response
• Protocol (PDF)
• Informed Consent 
• Frequently Asked Questions
• Key Personnel
  • BMT CTN # 0701 Protocol Chair: Ginna Laport, MD  
  • BMT CTN # 0701 Protocol Officer: Marcie Tomblyn, MD
  • BMT CTN # 0701 Medical Monitor: Gabrielle Meyers, MD
  • BMT CTN # 0701 Protocol Coordinator:  bmtctn@emmes.com
• Keywords: Follicular, Non-Hodgkin’s Lymphoma, NHL, Lymphoma, Allogeneic Transplant, Allo Transplant, Allo, Quality of Life, QOL, Fludarabine, Cyclophosphamide, Rituximab, FCR, Non-Myeloablative, Unrelated, Unrelated Donor, Pediatric, Child, Children, Teen, Adolescent

This study reached its target patient accrual on October 22, 2012 and is closed to new enrollment.

• Protocol Short Name and Number: NST Haploidentical, 0603
• Protocol Long Name: A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies
• Protocol (PDF)
• Informed Consent 
• Frequently Asked Questions
• Key Personnel 
  • BMT CTN # 0603 Protocol Co-chair: Ephraim Fuchs, MD  
  • BMT CTN # 0603 Protocol Co-chair: Paul O’Donnell, MD
  • BMT CTN # 0603 Protocol Officer: Mary Eapen, MD
  • BMT CTN # 0603 Protocol Coordinator: bmtctn@emmes.com
  • BMT CTN # 0603 Medical Monitor: Shannon Smiley, MD
• Keywords: Allo Transplant, Allogeneic Transplant, Allo, Haplo, Haploidentical, Non-Myeloablative, Hematologic malignancies, Leukemia, Lymphoma, Pediatric, Child, Children, Teen, Adolescent

This Study reached its target patient accrual on May 17, 2010 and is closed to new enrollment.

• Protocol Short Name and Number: NST for Elderly AML, 0502
• Protocol Long Name: A Phase II Study of Allogeneic Transplant for Older Patients with AML in First Morphologic Complete Remission using a Non-myeloblative Preparative Regimen
• Protocol (PDF)
• Protocol Synopsis/Schema (PDF)
• Informed Consents (PDF)
• Key Personnel
  • BMT CTN # 0502 Protocol Chair: Steven Devine, MD  
  • BMT CTN # 0502 BMT CTN Protocol Chair: Sergio Giralt, MD
  • Alliance Regulatory Group: regulatory@alliancenctn.org
• Keywords: Allo Transplant, Allogeneic Transplant, Allo, Unrelated, Unrelated Donor, Acute Myelogenous Leukemia, AML

Patient accrual on CALGB 100103/BMT CTN 0502 closed on December 29, 2011.

• Protocol Short Name and Number: Etanercept IPS, 0403
• Protocol Long Name: A Phase III, Randomized Double-Blind, Placebo Controlled Trial of Soluble Tumor Necrosis Factor Receptor: Enbrel (Etanercept) for the Treatment of Acute Non-Infectious Pulmonary Dysfunction (Idiopathic Pneumonia Syndrome) Following Allogeneic Stem Cell Transplantation
• Protocol (PDF)
• Informed Consent 
• Frequently Asked Questions
• Key Personnel
  • BMT CTN # 0403 Protocol Co-Chair: Ken Cooke, MD  
  • BMT CTN # 0403 Protocol Co-Chair: Greg Yanik, MD
  • BMT CTN # 0403 Protocol Officer: Mary Horowitz, MD
  • BMT CTN # 0403 Medical Monitor: Marcie Riches, MD
  • BMT CTN # 0403 Protocol Coordinator:  bmtctn@emmes.com
• Keywords: Etanercept, Enbrel, Idiopathic Pneumonia Syndrome, IPS

BMT CTN Protocol #0403 closed to patient accrual on September 14, 2011.

• Protocol Short Name and Number: Bexxar/BEAM,0401
• Protocol Long Name: Phase III Rituxan/BEAM vs. Bexxar/BEAM with Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-Cell Non-Hodgkin’s Lymphoma
• Protocol (PDF)
• Informed Consent
• Frequently Asked Questions
• Key Personnel
  • BMT CTN # 0401 Protocol Chair: Julie Vose, MD
  • BMT CTN # 0401 Protocol Officer: Marcie Tomblyn, MD
  • BMT CTN # 0401 Medical Monitor: Eneida Nemecek, MD
  • BMT CTN # 0401 Protocol Coordinator:  bmtctn@emmes.com
• Keywords: Bexxar, BEAM, Rituxan, Autologous Transplant, Auto Transplant, Auto, B-cell Lymphoma, Lymphoma, DLCBL

This study reached target accrual and closed to patient accrual on July 17, 2009.

• Protocol Short Name and Number: Acute GVHD, 0302
• Protocol Long Name: Initial Systemic Treatment of Acute GVHD: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox (Ontak), and Pentostatin in Combination with Corticosteroids
• Protocol (PDF)
• Consent Forms
• Frequently Asked Questions
• Key Personnel
  • BMT CTN # 0302 Protocol Chair: Dan Weisdorf, MD
  • BMT CTN # 0302 Protocol Officer: Marcelo Pasquini, MD  
  • BMT CTN # 0302 Medical Monitor: Mary Eapen, MD
  • BMT CTN # 0302 Protocol Coordinator:  bmtctn@emmes.com
• Keywords: Etanercept, Mycophenolate Mofetil, MMF, Denileukin Diftitox (Ontak), Pentostatin, Treatment, Pediatric, Graft versus Host Disease, GVHD, Graft vs. Host Disease, Child, Children, Teen, Adolescent

The BMT CTN #0302 study met its target accrual of 180 patients and closed enrollment on March 24, 2008.

• Protocol Short Name and Number: Follicular Lymphoma, 0202
• Protocol Long Name: Autologous vs. Non-Myeloablative Allogeneic Hematopoietic Stem Cell  Transplantation (HSCT) for Patients with Chemosensitive Follicular Non-Hodgkin’s  Lymphoma Beyond First Complete Response or First Partial Response
• Protocol (PDF)
• Informed Consents
• Frequently Asked Questions
• Key Personnel
  • BMT CTN # 0202  Protocol Co-Chair: Ginna Laport, MD  
  • BMT CTN # 0202  Protocol Co-Chair: Robert Negrin, MD  
  • BMT CTN # 0202  Protocol Officer:  Marcie Tomblyn, MD
  • BMT CTN # 0202  Protocol Medical Monitor: Mary Eapen, MD
  • BMT CTN # 0202  Protocol Coordinator:  bmtctn@emmes.com
• Keywords: Lymphoma, Follicular, Non-Hodgkin’s Lymphoma, NHL, Autologous Transplant, Auto Transplant, Auto, Allo Transplant, Allogeneic Transplant, Allo, Pediatric, Quality of Life, QOL, Non-myeloablative, Child, Children, Teen, Adolescent

This protocol closed to patient accrual on March 2, 2006.

• Protocol Short Name and Number: Multiple Myeloma, 0102
• Protocol Long Name: A Trial of Tandem Autologous Stem Cell Transplants +/- Post Second Autologous Transplant Maintenance Therapy versus Single Autologous Stem Cell Transplant Followed by Matched Sibling Non-myeloablative Allogeneic Stem Cell Transplant for Patients with Multiple Myeloma
• Protocol (PDF)
• Informed Consent Forms (.zip)
• Key Personnel
  • BMT CTN # 0102 Protocol Co-Chair: David Maloney, MD
  • BMT CTN # 0102 Protocol Co-Chair:  Amrita Krishnan, MD
  • BMT CTN # 0102 Protocol Officer:  Marcelo Pasquini, MD  
  • BMT CTN # 0102 Medical Monitor: Marcelo Pasquini, MD  
  • BMT CTN # 0102 Protocol Coordinator:  bmtctn@emmes.com
• Keywords: Multiple Myeloma, MM, Tandem, Auto Transplant, Autologous Transplant, Auto, Allo Transplant, Allogeneic Transplant, Allo, Non-Myeloablative, Quality of Life, QOL

This study reached the target accrual and closed to patient accrual on March 30, 2007.